217 related articles for article (PubMed ID: 35980649)
21. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
[TBL] [Abstract][Full Text] [Related]
22. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.
Kubota K; Nishiwaki Y; Sugiura T; Noda K; Mori K; Kawahara M; Negoro S; Watanabe K; Imamura F; Tamura T; Saijo N
Clin Cancer Res; 2005 Aug; 11(15):5534-8. PubMed ID: 16061870
[TBL] [Abstract][Full Text] [Related]
23. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.
William WN; Uyeki J; Johnson FM; Feng L; Peeples BO; Fossella FV; Karp DD; Blumenschein GR; Stewart DJ; Glisson BS
Cancer; 2010 May; 116(10):2409-15. PubMed ID: 20225329
[TBL] [Abstract][Full Text] [Related]
24. Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial.
Oh IJ; Kim KS; Park CK; Kim YC; Lee KH; Jeong JH; Kim SY; Lee JE; Shin KC; Jang TW; Lee HK; Lee KY; Lee SY
BMC Cancer; 2016 Aug; 16(1):690. PubMed ID: 27566413
[TBL] [Abstract][Full Text] [Related]
25. Prophylactic granulocyte-colony stimulating factor in patients with lung neuroendocrine carcinoma receiving platinum agents plus etoposide.
Watanabe H; Karayama M; Yasui H; Inoue Y; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suda T
Cancer Treat Res Commun; 2021; 29():100493. PubMed ID: 34844181
[TBL] [Abstract][Full Text] [Related]
26. Irinotecan plus cisplatin in patients with extensive-disease poorly differentiated neuroendocrine carcinoma of the esophagus.
Okuma HS; Iwasa S; Shoji H; Takashima A; Okita N; Honma Y; Kato K; Hamaguchi T; Yamada Y; Shimada Y
Anticancer Res; 2014 Sep; 34(9):5037-41. PubMed ID: 25202088
[TBL] [Abstract][Full Text] [Related]
27. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer.
Schmittel A; Sebastian M; Fischer von Weikersthal L; Martus P; Gauler TC; Kaufmann C; Hortig P; Fischer JR; Link H; Binder D; Fischer B; Caca K; Eberhardt WE; Keilholz U;
Ann Oncol; 2011 Aug; 22(8):1798-804. PubMed ID: 21266516
[TBL] [Abstract][Full Text] [Related]
28. Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509.
Satouchi M; Kotani Y; Shibata T; Ando M; Nakagawa K; Yamamoto N; Ichinose Y; Ohe Y; Nishio M; Hida T; Takeda K; Kimura T; Minato K; Yokoyama A; Atagi S; Fukuda H; Tamura T; Saijo N
J Clin Oncol; 2014 Apr; 32(12):1262-8. PubMed ID: 24638015
[TBL] [Abstract][Full Text] [Related]
29. A Phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206).
Eba J; Kenmotsu H; Tsuboi M; Niho S; Katayama H; Shibata T; Watanabe S; Yamamoto N; Tamura T; Asamura H; ;
Jpn J Clin Oncol; 2014 Apr; 44(4):379-82. PubMed ID: 24474818
[TBL] [Abstract][Full Text] [Related]
30. Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer.
Sun Y; Cheng Y; Hao X; Wang J; Hu C; Han B; Liu X; Zhang L; Wan H; Xia Z; Liu Y; Li W; Hou M; Zhang H; Xiu Q; Zhu Y; Feng J; Qin S; Luo X
BMC Cancer; 2016 Apr; 16():265. PubMed ID: 27061082
[TBL] [Abstract][Full Text] [Related]
31. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract.
Alhalabi O; Wilson N; Xiao L; Lin Y; Khandelwal J; Moussa MJ; Msaouel P; Navai N; Gao J; Kamat AM; Pilie P; Shah AY; Goswami S; Matin S; Kovitz C; Holla V; Guo C; Czerniak B; Logothetis C; Corn PG; Dinney CPN; Campbell MT; Hansel DE; Tannir NM; Siefker-Radtke AO
Eur Urol Oncol; 2023 Dec; 6(6):611-620. PubMed ID: 37833193
[TBL] [Abstract][Full Text] [Related]
32. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study.
Pujol JL; Daurès JP; Rivière A; Quoix E; Westeel V; Quantin X; Breton JL; Lemarié E; Poudenx M; Milleron B; Moro D; Debieuvre D; Le Chevalier T
J Natl Cancer Inst; 2001 Feb; 93(4):300-8. PubMed ID: 11181777
[TBL] [Abstract][Full Text] [Related]
33. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.
Jiang J; Liang X; Zhou X; Huang L; Huang R; Chu Z; Zhan Q
J Thorac Oncol; 2010 Jun; 5(6):867-73. PubMed ID: 20521354
[TBL] [Abstract][Full Text] [Related]
34. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
Furuse K; Fukuoka M; Nishiwaki Y; Kurita Y; Watanabe K; Noda K; Ariyoshi Y; Tamura T; Saijo N
J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212
[TBL] [Abstract][Full Text] [Related]
35. [Phase I Study of Etoposide and Cisplatin Chemotherapy Dose Escalation
with Concurrent Twice-daily Radiotherapy for Patients
with Limited-stage Small Cell Lung Cancer].
You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):55-60. PubMed ID: 28103974
[TBL] [Abstract][Full Text] [Related]
36. Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group.
Font A; Moyano AJ; Puerto JM; Tres A; Garcia-Giron C; Barneto I; Anton A; Sanchez JJ; Salvador A; Rosell R
Cancer; 1999 Feb; 85(4):855-63. PubMed ID: 10091762
[TBL] [Abstract][Full Text] [Related]
37. Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI).
Sekine I; Nishiwaki Y; Noda K; Kudoh S; Fukuoka M; Mori K; Negoro S; Yokoyama A; Matsui K; Ohsaki Y; Nakano T; Saijo N;
Ann Oncol; 2003 May; 14(5):709-14. PubMed ID: 12702524
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of Capecitabine Plus Irinotecan vs Irinotecan Monotherapy as Second-line Treatment in Patients With Advanced Gallbladder Cancer: A Multicenter Phase 2 Randomized Clinical Trial (GB-SELECT).
Ramaswamy A; Ostwal V; Sharma A; Bhargava P; Srinivas S; Goel M; Patkar S; Mandavkar S; Jadhav P; Parulekar M; Choudhari A; Gupta S
JAMA Oncol; 2021 Mar; 7(3):436-439. PubMed ID: 33270098
[TBL] [Abstract][Full Text] [Related]
39. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Senan S; Brade A; Wang LH; Vansteenkiste J; Dakhil S; Biesma B; Martinez Aguillo M; Aerts J; Govindan R; Rubio-Viqueira B; Lewanski C; Gandara D; Choy H; Mok T; Hossain A; Iscoe N; Treat J; Koustenis A; San Antonio B; Chouaki N; Vokes E
J Clin Oncol; 2016 Mar; 34(9):953-62. PubMed ID: 26811519
[TBL] [Abstract][Full Text] [Related]
40. Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis.
Jiang S; Huang L; Zhen H; Jin P; Wang J; Hu Z
BMC Cancer; 2021 Dec; 21(1):1308. PubMed ID: 34876060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
